Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2010

01-10-2010 | Editorial

Drug-Induced Acute Pancreatitis: Underdiagnosis and Overdiagnosis

Author: Scott Tenner

Published in: Digestive Diseases and Sciences | Issue 10/2010

Login to get access

Excerpt

As the incidence of acute pancreatitis continues to rise, establishing the etiology in order to prevent recurrence is important [1, 2]. Although the etiology of acute pancreatitis is not difficult in the majority of patients, almost a quarter of patients are initially labeled as having idiopathic acute pancreatitis [3]. When confronted with a patient with acute pancreatitis and no clear etiology defined as an absence of a history of alcoholism, absence of imaging demonstrating gallstones (ultrasound and/or MRI), and a normal triglyceride level, it is reasonable to consider a drug as the cause of acute pancreatitis. When considering a particular medication as causing acute pancreatitis, often the first step is a literature search. Data from pharmaceutical companies and/or the Food and Drug Administration (FDA) is not helpful. Typically, these sources cite many medications as causing acute pancreatitis despite the fact that the evidence provided does not have sufficient detail as to demonstrate causation. Published case reports, if detailed properly, can give more definitive information as to the diagnosis of acute pancreatitis and whether other causes besides drugs have been properly ruled out. …
Literature
1.
go back to reference Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systemic review. Pancreas. 2006;3:323–330.CrossRef Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systemic review. Pancreas. 2006;3:323–330.CrossRef
2.
go back to reference Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing United States hospital admissions for acute pancreatitis, 1988–2003. Ann Epidemiol. 2007;17:491–497.CrossRefPubMed Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing United States hospital admissions for acute pancreatitis, 1988–2003. Ann Epidemiol. 2007;17:491–497.CrossRefPubMed
3.
go back to reference Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379–2400.CrossRefPubMed Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379–2400.CrossRefPubMed
4.
go back to reference Badalov N, Baradarian R, Iswara K, Li JJ, Steinberg W, Tenner S. Drug induced acute pancreatitis: an evidence based review. Badalov N, Baradarian R, Iswara K, Li JJ, Steinberg W, Tenner S. Drug induced acute pancreatitis: an evidence based review.
6.
go back to reference Mallory A, Kern F Jr. Drug induced pancreatitis: a critical review. Gastroenterology. 1980;78:813–820.PubMed Mallory A, Kern F Jr. Drug induced pancreatitis: a critical review. Gastroenterology. 1980;78:813–820.PubMed
7.
go back to reference Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39:708–716.CrossRef Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39:708–716.CrossRef
8.
Metadata
Title
Drug-Induced Acute Pancreatitis: Underdiagnosis and Overdiagnosis
Author
Scott Tenner
Publication date
01-10-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1367-2

Other articles of this Issue 10/2010

Digestive Diseases and Sciences 10/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine